Drug Watch

Latest News

brain
Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia

May 12th 2025

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

alcohol refusal
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04

May 8th 2025

depression
FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal Depression

May 1st 2025

pills
April in Review: Updates on the Psychiatric Treatment Pipeline

April 30th 2025

borderline personality disorder
First-of-its-Kind Study: Using a Novel Platform to Assess Patients With Borderline Personality Disorder

April 29th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.